Directed Evolution of AAV Serotype 5 for Increased Hepatocyte Transduction and Retained Low Humoral Seroreactivity
Open Access
- 1 March 2021
- journal article
- research article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 20, 122-132
Abstract
No abstract availableKeywords
Funding Information
- Eshelman Innovation
This publication has 44 references indexed in Scilit:
- Immune responses to AAV vectors: overcoming barriers to successful gene therapyBlood, 2013
- Enhanced Sialic Acid-Dependent Endocytosis Explains the Increased Efficiency of Infection of Airway Epithelia by a Novel Adeno-Associated VirusJournal of Virology, 2011
- Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV VectorsHuman Gene Therapy, 2010
- Directed evolution of adeno-associated virus to an infectious respiratory virusProceedings of the National Academy of Sciences, 2009
- A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selectionProceedings of the National Academy of Sciences, 2009
- In Vitro and In Vivo Gene Therapy Vector Evolution via Multispecies Interbreeding and Retargeting of Adeno-Associated VirusesJournal of Virology, 2008
- Prevalence of Neutralizing Antibodies Against Adeno-Associated Virus (AAV) Types 2, 5, and 6 in Cystic Fibrosis and Normal Populations: Implications for Gene Therapy Using AAV VectorsHuman Gene Therapy, 2006
- Structure of Adeno-Associated Virus Serotype 5Journal of Virology, 2004
- Rapid Uncoating of Vector Genomes Is the Key toEfficient Liver Transduction with Pseudotyped Adeno-Associated VirusVectorsJournal of Virology, 2004
- Molecular evolution by staggered extension process (StEP) in vitro recombinationNature Biotechnology, 1998